视网膜疾病治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球视网膜疾病治疗市场价值为 183 亿美元，预计到 2034 年将以 6.7% 的复合年增长率增长，达到 348 亿美元，这主要得益于糖尿病及其併发症如糖尿病视网膜病变 (DR) 和糖尿病黄斑水肿 (DME) 的日益普及。视网膜疾病治疗涵盖一系列医疗、外科和药物干预措施，包括抗 VEGF 注射、雷射治疗、皮质类固醇治疗和玻璃体切除术。这些治疗的主要目标是防止进一步的视网膜损伤并保留或恢復视力。治疗方法的选择取决于病情的严重程度、疾病的分期以及患者眼睛的整体健康状况。 DME 是视力丧失的主要原因，尤其是在第 2 型糖尿病患者中，这凸显了及时介入和专门护理的必要性。

缓释眼内疗法等治疗方法的最新进展，透过减少注射频率提高了患者的依从性。例如，某些注射装置设计用于持续给药，从而减轻了频繁的眼部注射。这些创新有助于最大限度地减轻治疗负担，同时为视网膜疾病提供更有效的解决方案。

黄斑部病变，尤其是老年黄斑部病变 (AMD)，在 2024 年占据了市场主导地位，占 55%。 AMD 主要影响 60 岁以上的人，是该年龄层视力丧失的主要原因之一。随着全球人口老化，高血压和肥胖等合併症进一步加剧了 AMD 的盛行率，推动了对持续研究和治疗创新的需求。

注射剂是市场的关键驱动力，2024 年占 63.5%。玻璃体内注射通常用于治疗视网膜疾病，例如老年黄斑部病变 (AMD)、视网膜静脉阻塞和糖尿病黄斑水肿 (DME)。抗 VEGF 疗法已在治疗这些疾病方面显示出良好的效果，因为它们能够快速起效。阿瓦斯汀 (Avastin)、阿柏西普 (Eylea) 和雷珠单抗 (Lucentis) 等药物已被证明能够有效减少视网膜水肿和新生血管形成，最终改善患者的视力。

美国视网膜疾病治疗市场规模预计将从2024年的71亿美元增长至2034年的131亿美元，主要得益于老龄化人口对视网膜疾病的易感性，以及先进的玻璃体内注射疗法的普及。此外，优惠的健保政策和主要製药商的强劲影响力将继续推动市场扩张。

全球视网膜疾病治疗市场的主要参与者包括再生元製药、拜耳、艾伯维、诺华、辉瑞和罗氏。这些公司正在加大研发和新产品开发方面的投入，以在竞争中保持领先地位。为了巩固其在视网膜疾病治疗市场的地位，各公司正致力于扩大产品组合併推广治疗技术。关键策略包括建立合作关係，以利用药物开发和分销方面互补的专业知识。此外，各公司也透过创新的给药系统和改进的报销结构来改善病患治疗效果。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 糖尿病盛行率不断上升
    • 老年人口不断增加
    • 技术进步
    • 提高认识和筛检项目
  • 产业陷阱与挑战
    • 治疗费用高
    • 副作用和安全问题
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 各国应对措施
  • 对产业的影响
    • 供应方影响（製造成本）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（消费者成本）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 技术格局
• 未来市场趋势
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 - 2034 年

• 主要趋势
• 黄斑部病变
  • 湿性黄斑部病变
  • 干性黄斑部病变
• 糖尿病视网膜病变
• 遗传性视网膜疾病（IRD）
• 糖尿病黄斑水肿
• 视网膜静脉阻塞
• 其他类型

第六章：市场估计与预测：按剂型，2021 - 2034 年

• 主要趋势
• 胶囊和片剂
• 眼药水
• 眼部护理
• 凝胶
• 软膏
• 注射

第七章：市场估计与预测：按配销通路，2021 - 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• AbbVie
• Alimera Sciences
• Amgen
• Apellis Pharmaceuticals
• Astellas Pharma
• Bayer
• Biogen
• Bausch + Lomb
• Celltrion
• F. Hoffmann-La Roche
• Novartis
• Pfizer
• Regeneron Pharmaceutical
• Santen Pharmaceuticals
• Sandoz Group

The Global Retinal Disorder Treatment Market was valued at USD 18.3 billion in 2024 and is estimated to grow at a CAGR of 6.7% to reach USD 34.8 billion by 2034, driven by the increasing prevalence of diabetes, along with its complications such as diabetic retinopathy (DR) and diabetic macular edema (DME). Retinal disorder treatments encompass a range of medical, surgical, and pharmaceutical interventions, including anti-VEGF injections, laser therapy, corticosteroid treatments, and vitrectomy. The primary goal of these treatments is to prevent further retinal damage and preserve or restore vision. The selection of a treatment depends on the severity of the condition, the stage of the disorder, and the overall health of the patient's eye. DME is a leading cause of vision loss, particularly among individuals with type 2 diabetes, highlighting the need for timely interventions and specialized care.

Recent advancements in treatment methods, such as sustained-release intraocular therapies, enhance patient compliance by reducing the frequency of injections. For example, certain injectable devices are designed for continuous drug delivery, offering relief from frequent eye injections. These innovations are helping to minimize the treatment burden while providing more effective solutions for retinal disorders.

Macular degeneration, particularly age-related macular degeneration (AMD), dominated the market in 2024, accounting for a 55% share. AMD, which primarily affects individuals over 60 years old, is one of the leading causes of vision loss in this age group. As the global population ages, comorbidities such as hypertension and obesity further exacerbate the prevalence of AMD, driving the need for continued research and treatment innovation.

The injection segment is a key driver in the market, accounting for 63.5% share in 2024. Intravitreal injections are commonly used for treating retinal conditions like AMD, retinal vein occlusion, and DME. Anti-VEGF therapies have shown promising results in treating these conditions, as they offer rapid therapeutic responses. Drugs such as Avastin, Eylea, and Lucentis are proving effective in reducing retinal edema and neovascularization, ultimately improving visual acuity for patients.

United States Retinal Disorder Treatment Market is poised to grow from USD 7.1 billion in 2024 to USD 13.1 billion by 2034, driven by the aging population susceptible to retinal conditions and the widespread availability of advanced intravitreal injection therapies. Moreover, favorable reimbursement policies and the strong presence of key pharmaceutical manufacturers continue to fuel market expansion.

Key players in the Global Retinal Disorder Treatment Market include Regeneron Pharmaceuticals, Bayer, AbbVie, Novartis, Pfizer, and F. Hoffmann-La Roche. These companies are investing in R&D and new product development to stay ahead in the competitive landscape. To strengthen their position in the retinal disorder treatment market, companies are focusing on expanding their product portfolios and advancing treatment technologies. Key strategies include forming partnerships to leverage complementary expertise in drug development and distribution. Furthermore, companies are enhancing patient treatment through innovative drug delivery systems and improved reimbursement structures.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes
    • 3.2.1.2 Rising geriatric population
    • 3.2.1.3 Technological advancements
    • 3.2.1.4 Rising awareness and screening programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Country-wise response
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (cost of manufacturing)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (cost to consumers)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Technological landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Macular degeneration
  • 5.2.1 Wet macular degeneration
  • 5.2.2 Dry macular degeneration
• 5.3 Diabetic retinopathy
• 5.4 Inherited retinal diseases (IRDs)
• 5.5 Diabetic macular edema
• 5.6 Retinal vein occlusion
• 5.7 Other types

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Capsules and tablets
• 6.3 Eye drops
• 6.4 Eye solutions
• 6.5 Gels
• 6.6 Ointments
• 6.7 Injections

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Alimera Sciences
• 9.3 Amgen
• 9.4 Apellis Pharmaceuticals
• 9.5 Astellas Pharma
• 9.6 Bayer
• 9.7 Biogen
• 9.8 Bausch + Lomb
• 9.9 Celltrion
• 9.10 F. Hoffmann-La Roche
• 9.11 Novartis
• 9.12 Pfizer
• 9.13 Regeneron Pharmaceutical
• 9.14 Santen Pharmaceuticals
• 9.15 Sandoz Group